Dishman Carbogen Amcis Limited — Investor Meet, 18-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Financial Performance: Dishman Carbogen Amcis Limited reported a revenue of INR 682 crores for the third quarter, marking a 9% year-over-year increase. For the nine months ended December 31, 2024, total revenue reached INR 1,995 crores, up from INR 1,961 crores in the prior year. The company achieved an EBITDA of INR 140.6 crores for Q3, illustrating a substantial increase from INR 42.5 crores in Q3 of FY 2024, leading to an operating margin of 20.6%. Between the nine-month periods, EBITDA rose from INR 232 crores to INR 318.5 crores.

Future Outlook and Growth Drivers: Management expressed confidence in achieving forecasts for the coming year, bolstered by successful audits in France and China, which may enhance growth prospects significantly in those markets. The strategic focus includes a robust pipeline in commercial production that has recently gained traction, especially in Switzerland and India.

Order Book and Operational Updates: The company announced successful audits in France and China, confirming their readiness for expanded operations. Additionally, new customer acquisitions are anticipated to enhance revenue growth.

Analyst Q&A Insights: Analysts raised concerns about profit inconsistencies, particularly a drop in profit before tax to INR 27 crores, attributed to increased finance costs and operational challenges. Management reassured stakeholders that efforts are being made to stabilize finance costs moving forward.

Market or Regulatory Updates: No significant regulatory updates discussed pertain directly to Dishman’s operations, but market growth potential remains robust in pharmaceuticals, particularly with the anticipated market certification in key regions.

Strategic Focus Areas: There's a clear emphasis on operational efficiency, cost control, and collaboration between Dishman and Carbogen Amcis, aiming for enhanced market penetration.

Investor Insight: The company's recent financial performance and growth strategies suggest a favorable outlook, aligning with a 'buy' position, particularly given the significant improvement in operational metrics and anticipated growth in emerging markets.